MMAB Drug Discovery Landscape & Assay Solutions

  • By admin
  • 02 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Methylmalonic Acidemia (cblB Type) Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for MMAB (Cob(I)alamin Adenosyltransferase) drug discovery targeting methylmalonic acidemia. Select your modality below:

Component / Network Product Description Product Link
Antigen MMAB Recombinant Protein (WT & Pathogenic Mutants)
High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Includes key disease variants (p.Gly94Arg, p.Arg190Trp) for chaperone screening.		 View MMAB Products
Gene Delivery MMAB Promise-ORF / Lentivirus
Mitochondrial-targeted ORF for stable cell line generation. HEK293 expressed with native MTS.		 View MMAB Products
Detector Anti-MMAB Recombinant Antibody
Rabbit monoclonal for detection and immunogenicity assays. Suitable for mitochondrial localization studies.		 View MMAB Products
Validator MMAB siRNA Set
For knockdown verification in patient fibroblast models and assay specificity control.		 View MMAB Products
Related Target: MMUT Methylmalonyl-CoA Mutase
Downstream enzyme requiring AdoCbl (product of MMAB). Epistatic pathway partner.		 View MMUT Products
Related Target: MMADHC Methylmalonic Aciduria and Homocystinuria Type D
Cobalamin trafficking protein. Synergistic cofactor delivery pathway.		 View MMADHC Products

Critical Assay Challenges & TarMart Advantage

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Pathogenic Variant Enzyme Activity Profiling Purified WT and Mutant MMAB proteins (>95% purity) with verified mitochondrial import sequences for ATP/cob(I)alamin binding assays.
Mitochondrial Localization Validation Full-length ORF with native mitochondrial targeting signal (MTS) in Lentiviral format for stable HEK293 integration.
Cofactor Binding Quantification High-purity apo-protein format available for adenosylcobalamin (AdoCbl) loading studies.
False Positives in Cell Rescue Validated siRNA included for specificity controls in complementation assays.

Live MMAB R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The therapeutic landscape for MMAB-deficient methylmalonic acidemia (cblB type) is experiencing a paradigm shift from dietary management and organ transplantation to precision genetic medicines. With MMAB being the rate-limiting enzyme for adenosylcobalamin (AdoCbl) synthesis, the current R&D focus centers on restoring enzymatic activity within the mitochondrial matrix. Key disease mutations include p.Gly94Arg and p.Arg190Trp, which affect enzyme stability and ATP binding.

"The transition from palliative care to curative interventions for MMAB deficiency is accelerating, with mRNA therapies demonstrating early clinical efficacy and AAV-based gene therapy programs advancing toward the clinic. As first-in-human data emerges, the critical R&D bottleneck has shifted toward developing robust biochemical assays that can distinguish between total protein restoration and functional catalytic activity restoration."

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
mRNA Therapy Moderna (mRNA-3705) Isolated MMA (cblB) Functional Enzyme Activity Assay (Need purified WT MMAB as positive control; mutant proteins for patient variant profiling)
AAV Gene Therapy Ultragenyx, Forge Biologics Organic Acidemias Subcellular Localization Assay (Need full-length ORF lentivirus for mitochondrial targeting validation)
Pharmacological Chaperones Preclinical Academic Mis-sense Mutations (G94R, R190W) Protein Stability Assay (Need purified pathogenic mutant proteins for thermal shift/binding assays)
Enzyme Replacement Preclinical/IND-enabling Acute Metabolic Decompensation Endocytosis/Mitochondrial Import Assay (Need recombinant protein with intact MTS)